Clinical Drug Experience Knowledgebase

allogeneic bone marrow (1 trial)

allogeneic stem cells (3 trials)

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (1 trial)

aprepitant (Emend) (1 trial)

arsenic trioxide (trisenox) (1 trial)

artesunate (1 trial)

asparaginase (elspar) (5 trials)

autologous hematopoietic stem cells (2 trials)

autologous mononuclear stem cell (3 trials)

bortezomib (velcade) (16 trials)

cyclophosphamide (cytoxan) (10 trials)

cyclosporine (sandimmune) (1 trial)

cytarabine (cytosar-u) (25 trials)

daunorubicin (cerubidine) (8 trials)

doxorubicin (Doxil) (3 trials)

etoposide (vepesid) (4 trials)

Filgrastim (neupogen) (3 trials)

fludarabine (fludara) (7 trials)

gemtuzumab ozogamicin (mylotarg) (1 trial)

granisetron (kytril) (1 trial)

idarubicin (idamycin) (11 trials)

imatinib (gleevec) (3 trials)

interferon alpha-2b (Intron-A) (2 trials)

lenalidomide (revlimid) (11 trials)

mercaptopurine (purinethol) (6 trials)

mitoxantrone (novantrone) (3 trials)

naltrexone (revia) (10 trials)

palonosetron (aloxi) (1 trial)

prednisone (meticorten) (15 trials)

pyrimethamine (daraprim) (1 trial)

rituximab (rituxan) (4 trials)

sargramostim (leukine) (4 trials)

sulfadoxine (1 trial)

teniposide (vumon) (1 trial)

thalidomide (Thalomid) (3 trials)

topotecan (hycamtin) (1 trial)

tretinoin (Retin-A) (4 trials)

urea (18 trials)

vincristine (oncovin) (12 trials)

voriconazole (vfend) (1 trial)

zoledronic acid (zometa) (1 trial)

acalabrutinib (calquence) (1 trial)

azacitidine (vidaza) (4 trials)

busulfan (Myleran) (1 trial)

carfilzomib (kyprolis) (4 trials)

carmustine (bicnu) (1 trial)

clarithromycin (biaxin) (1 trial)

daratumumab (darzalex) (4 trials)

dexamethasone (8 trials)

Iberdomide (2 trials)

Isatuximab (Sarclisa) (1 trial)

ixazomib (ninlaro) (1 trial)

melphalan (alkeran) (8 trials)

pevonedistat (1 trial)

amphotericin b (fungizone) (1 trial)

autologous cd133+ stem cells (1 trial)

belantamab mafodotin (TECVAYLI) (2 trials)

bendamustine (treanda) (1 trial)

beta erythropoietin (1 trial)

blinatumomab (blincyto) (1 trial)

bosutinib (bosulif) (1 trial)

clofarabine (clolar) (1 trial)

dasatinib (sprycel) (1 trial)

filanesib (1 trial)

hydrocortisone (solu-cortef) (1 trial)

ibritumomab tiuxetan (Zevalin) (1 trial)

ibrutinib (imbruvica) (1 trial)

idelalisib (zydelig) (1 trial)

ifosfamide (ifex) (1 trial)

methotrexate (1 trial)

panobinostat (farydak) (1 trial)

pembrolizumab (keytruda) (1 trial)

plerixafor (mozobil) (1 trial)

pomalidomide (pomalyst) (2 trials)

ponatinib (iclusig) (1 trial)

quizartinib (VANFLYTA) (3 trials)

selinexor (Xpovio) (2 trials)

Talquetamab (Talvey) (1 trial)

teclistamab (Tecvayli) (1 trial)

valganciclovir (Valcyte) (1 trial)

venetoclax (venclexta) (1 trial)

vindesine (Eldisine) (1 trial)

elotuzumab (empliciti) (1 trial)

nivolumab (opdivo) (1 trial)